[HTML][HTML] Chromosome 1q21 abnormalities in multiple myeloma
Abstract Gain of chromosome 1q (+ 1q) is one of the most common recurrent cytogenetic
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …
IMWG consensus on risk stratification in multiple myeloma
Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which
translates to variable response to treatment and outcome. With the recent increase in …
translates to variable response to treatment and outcome. With the recent increase in …
Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
A Palumbo, H Avet-Loiseau, S Oliva… - Journal of clinical …, 2015 - ascopubs.org
Purpose The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and
reliable tool is needed to stratify patients with MM. We combined the International Staging …
reliable tool is needed to stratify patients with MM. We combined the International Staging …
[HTML][HTML] Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised …
GH Jackson, FE Davies, C Pawlyn, DA Cairns… - The Lancet …, 2019 - thelancet.com
Background Patients with multiple myeloma treated with lenalidomide maintenance therapy
have improved progression-free survival, primarily following autologous stem-cell …
have improved progression-free survival, primarily following autologous stem-cell …
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
P Sonneveld, H Avet-Loiseau, S Lonial… - Blood, The Journal …, 2016 - ashpublications.org
Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …
Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma
Purpose At the molecular level, myeloma is characterized by copy number abnormalities
and recurrent translocations into the immunoglobulin heavy chain locus. Novel methods …
and recurrent translocations into the immunoglobulin heavy chain locus. Novel methods …
[HTML][HTML] European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European …
D Averbuch, C Orasch, C Cordonnier… - …, 2013 - ncbi.nlm.nih.gov
Owing to increasing resistance and the limited arsenal of new antibiotics, especially against
Gram-negative pathogens, carefully designed antibiotic regimens are obligatory for febrile …
Gram-negative pathogens, carefully designed antibiotic regimens are obligatory for febrile …
The genetic architecture of multiple myeloma
Based on the clinical features of myeloma and related malignancies of plasma cells, it has
been possible to generate a model system of myeloma progression from a normal plasma …
been possible to generate a model system of myeloma progression from a normal plasma …
[HTML][HTML] Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
TM Schmidt, BG Barwick, N Joseph, LT Heffner… - Blood Cancer …, 2019 - nature.com
Abstract Gain of chromosome 1q (+ 1q) is commonly identified in multiple myeloma and has
been associated with inferior outcomes. However, the prognostic implication of+ 1q has not …
been associated with inferior outcomes. However, the prognostic implication of+ 1q has not …
[HTML][HTML] Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing
J Li, NJ Stagg, J Johnston, MJ Harris, SA Menzies… - Cancer cell, 2017 - cell.com
Summary The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell
lineage marker FcRH5 expressed in multiple myeloma (MM) tumor cells. We demonstrate …
lineage marker FcRH5 expressed in multiple myeloma (MM) tumor cells. We demonstrate …